Status of therapies in development for the treatment of age-related macular degeneration

IDrugs

Volumn 6, Issue 5, 2003, Pages 464-469

  Hunt, David W C ^a   Margaron, Philippe ^a  

^a QLT Inc   (United States)

Author keywords

Age related macular degeneration; Anti angiogenics; Anti inflammatories; Choroidal neovascularization; Photo dynamic therapy

Indexed keywords

AMFENAC; ANECORTAVE; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; APTAMER; ATX S 10; BENZOPORPHYRIN DERIVATIVE; COMBRETASTATIN A4 PRODRUG; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ETIOPURPURIN; FLUOCINOLONE ACETONIDE; LUTETIUM TEXAPHYRIN; NEPAFENAC; PEGAPTANIB; PHOTOSENSITIZING AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; PLANT EXTRACT; PORPHYRIN DERIVATIVE; RECOMBINANT ANTIBODY; RECOMBINANT HUMAN VASCULOTROPIN MONOCLONAL ANTIBODY V2; ROSTAPORFIN; SQUALAMINE; STEROID; TIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

BLOOD VESSEL INJURY; CLINICAL TRIAL; COMBRETUM; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MANUFACTURE; DRUG SAFETY; DRUG STRUCTURE; ELDERLY CARE; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LASER COAGULATION; NONHUMAN; PHARMACEUTICAL CARE; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SUSTAINED RELEASE PREPARATION; VISUAL IMPAIRMENT; WETTABILITY;

ANIMALS; HUMANS; MACULAR DEGENERATION; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037531605     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Fine SL, Berger JW, Maguire MG, Ho AC: Age-related macular degeneration. N Engl J Med (2000) 342:483-492.
2. Thompson J, Daniels C: Wet-type macular degeneration. Radiol Technol (1998) 70:85-88.
3. Soubrane G, Bressler NM: Treatment of subfoveal choroidal neovascularization in age related macular degeneration: Focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol (2001) 85:483-495.
4. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Miller DT, Yannzzi LA et al: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. J Am Med Assoc (1994) 272:1413-1420.
5. Hammond BR Jr, Johnson MA: The age-related eye disease study (AREDS). Nutr Rev (2002) 60:283-288.
6. Brown SB, Mellish KJ: Verteporfin: A milestone in ophthalmology and photodynamic therapy. Exp Opin Pharmacother (2001) 2:351-361.
7. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q: Photodynamic therapy. J Natl Cancer Inst (1998) 90:889-905. This review covers the localization of photosensitizing agents, and the molecular, cellular and tumor responses associated with PDT.
8. Granville DJ, McManus BM, Hunt DW: Photodynamic therapy: Shedding light on the biochemical pathways regulating porphyrin-mediated cell death. Histol Histopathol (2001) 16:309-317.
9. Schmidt-Erfurth U, Hasan T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol (2000) 45:195-214.
10. Granville DJ, Shaw JR, Leong S, Carthy CM, Margaron P, Hunt DW, McManus BM: Release of cytochrome c, Bax migration, Bid cleavage, and activation of caspases 2, 3, 6, 7, 8, and 9 during endothelial cell apoptosis. Am J Pathol (1999) 155:1021-1025.
11. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators: Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina (2002) 22:6-18.
12. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol (1999) 117:1329-1345.
13. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K et al: Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: Additional information regarding baseline lesion composition's impact on vision outcomes - TAP report No. 3. Arch Ophthalmol (2002) 120:1443-1454.
14. Lim JI: Photodynamic therapy for choroidal neovascular disease: Photosensitizers and clinical trials. Ophthalmol Clin North Am (2002) 15:473-478.
15. Renno RZ, Miller JW: Photosensitizer delivery for photodynamic therapy for choroidal neovascularization. Adv Drug Deliv Rev (2001) 52:63-78.
16. Obana A, Gohto Y, Kaneda K, Nakajima S, Takemura T, Miki T: Selective occlusion of choroidal neovascularization by photodynamic therapy with a water-soluble photosensitizer, ATX-S10. Lasers Surg Med (1999) 24:209-222.
17. Obana A, Gohto Y, Kaneda K, Nakajima S, Miki T: PDT to monkey CNV with ATX-S10(Na): Inappropriateness of early laser irradiation for selective occlusion. Invest Ophthalmol Vis Sci (2001) 42:2639-2645.
18. Woodburn KW, Engelman CJ, Blumenkranz MS: Photodynamic therapy for choroidal neovascularization: A review. Retina (2002) 22:391-405.
19. Folkman J: Angiogenesis-dependent diseases. Semin Oncol (2001) 28:536-542.
20. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science (1999) 285:245-248.
21. Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, Hayano M, Murota SI, Mochizuki M: Novel mechanism for age-related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol (2001) 189:323-333. This review examines the balance between PEDF and VEGF, and examines the theory that PEDF may counteract the angiogenic properties of VEGF.
22. Kwak N, Okamoto N, Wood JM, Campochiaro PA: VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci (2000) 41:3158-3164.
23. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 120:338-346.
24. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE: Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol (2000) 157:135-144.
25. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC, Bendele RA: Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res (2000) 17:1503-1510.
26. The Eyetech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF PEGylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 22:143-152.
27. Singerman LJ: Anti-VEGF therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase IB results. Invest Ophthalmol Vis Sci (2002) 43:Abs 2908.
28. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 120:338-346.
29. Rosenfeld PJ, Villate N, Feuer WJ, Puliafito CA, McCluskey ER: RhuFab V2 (anti-VEGF antibody fragment) in neovascular AMD: Safety, tolerability, and efficacy of multiple, escalating dose intravitreal injections. Ann Meet Assoc Res Vision Ophthalmol, Fort Lauderdale, FL, USA (2003):Abs 972.
30. Heier JS, Sy JR, McCluskey ER: RhuFab V2 in Wet AMD - 6 month continued improvement following multiple intravitreal injections. Ann Meet Assoc Res Vision Ophthalmol, Fort Lauderdale, FL, USA (2003):Abs 972.
31. Holekamp NM, Bouck N, Volpert O: Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol (2002) 134:220-227.
32. Renno RZ, Youssri AI, Michaud N, Gragoudas ES, Miller JW: Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 43:1574-1580.
33. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA: Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci (2002) 43:2428-2434.
34. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q, Berns KI, Raisler BJ, Hauswirth WW, Campochiaro PA: AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 43:1994-2000.
35. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU: Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther (2001) 12:2029-2032.
36. Griggs J, Metcalfe JC, Hesketh R: Targeting tumour vasculature: The development of combretastatin A4. Lancet Oncol (2001) 2:82-87.
37. Armstrong D, Higa A, Iwabuchi S, Wood M: Vascular targeting activity of combretastatin A-4 phosphate (CA4P) in an ocular model of angiogenesis. Invest Ophthalmol Vis Sci (2002) 43:Abs 1752.
38. Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina (2000) 20:244-250.
39. Yoshikawa K, Kotake S, Ichiishi A, Sasamoto Y, Kosaka S, Matsuda H: Posterior sub-tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol (1995) 39: 71-76.
40. Jonas JB, Hayler JK, Panda-Jonas S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol (2000) 84:1064-1067.
41. Gillies MC, Chua W, Mitchell P, Billson F, Hunyor A, Penfold P, Simpson J: Photographic and fluorescein angiographic outcomes from the intravitreal triamcinolone study for neovascular Armd. Invest Ophthalmol Vis Sci (2002) 43: Abs 2907.
42. Spaide RF, Sorenson J: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ann Meet Assoc Res Vision Ophthalmol, Fort Lauderdale, FL, USA (2003):Abs 5032.
43. Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation (2000) 24:371-384.
44. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation (2000) 24:357-370.
45. Takahashi K, Saishin Y, Saishin Y, Mori K, Ando A, Yamamoto S, Oshima Y, Nambu H, Melia MB, Bingaman DP, Campochiaro PA: Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci (2003) 44:409-415.
46. Slakter JS, Singerman LJ, Yannuzzi LA, Russell SR, Hudson HL, Jerdan J, Zilliox P, Robertson S: Sub-Tenon's administration of the angiostatic agent anecortave acetate in AMD patients with subfoveal choroidal neovascularization (CNV) - The clinical outcome. Invest Ophthalmol Vis Sci (2002) 43:Abs 2909.
47. Penn JS, Rajaratnam VS, Collier RJ, Clark AF: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci (2001) 42:283-290.
48. Alcon Inc: Alcon launches new anecortave acetate clinical trial for macular degeneration based on positive results from ongoing studies. Press Release (2002) September 03.
49. Higgins RD, Sanders RJ, Yan Y, Zasloff M, Williams JI: Squalamine improves retinal neovascularization. Invest Ophthalmol Vis Sci (2000) 41:1507-1512.
50. Genaidy M, Kazi AA, Peyman GA, Passos-Machado E, Farahat HG, Williams JI, Holroyd KJ, Blake DA: Effect of squalamine on iris neovascularization in monkeys. Retina (2002) 22:772-778.
51. Sills AK Jr, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA et al: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res (1998) 58:2784-2792.
52. Stone TW, Sternberg P Jr: Submacular surgery trials update. Ophthalmol Clin North Am (2002) 15:479-488.
53. Ciulla TA, Harris A, Kagemann L, Danis RP, Maturi R, McNulty L, Pratt LM, Xiao M, Criswell MH, Weinberger D: Transpupillary thermotherapy for subfoveal occult choroidal neovascularization: Effect on ocular perfusion. Invest Ophthalmol Vis Sci (2001) 42:3337-3340.
54. Flaxel CJ: Use of radiation in the treatment of age-related macular degeneration. Ophthalmol Clin North Am (2002) 15:437-444.
55. Kaven C, Spraul CW, Zavazava N, Lang GK, Lang GE: Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro. Ophthalmologica (2001) 215:284-289.